This article has Open Peer Review reports available.
Fibrinogen storage disease without hypofibrinogenemia associated with estrogen therapy
© Simsek et al; licensee BioMed Central Ltd. 2005
Received: 21 February 2005
Accepted: 15 November 2005
Published: 15 November 2005
Cytoplasmic inclusion bodies within hepatocytes may have different etiologies, including the Endoplasmic Reticulum Storage Diseases (ERSDs). ERSD is a pathological condition characterized by abnormal accumulation of proteins destined for secretion in the endoplasmic reticulum of hepatocytes; it may be congenital (primary) or acquired (secondary). Fibrinogen storage disease is a form of ERSD.
We present a case of fibrinogen storage disease secondary to estrogen replacement therapy. Its causal relationship to the drug is shown by histological, immunohistochemical and ultrastructural studies of paired liver biopsies obtained during and after the drug therapy.
The liver biopsies of patients with idiopathic liver enzyme abnormalities should be carefully evaluated for cytoplasmic inclusion bodies and, although rare, fibrinogen deposits.
Cytoplasmic inclusions in hepatocytes are encountered in a wide range of clinical conditions including chronic hepatitis B, α1-antitrypsin deficiency, type IV glycogenosis, Lafora's disease, fibrinogen storage disease, and in drug reactions [1, 2]. Endoplasmic Reticulum Storage Disease (ERSD) of the liver is a pathological condition characterized by abnormal accumulation of proteins destined for secretion in the endoplasmic reticulum. The term ERSD encompasses α1-antitrypsin deficiency, the prototype disorder, plus fibrinogen storage disease and α1-antichymotrypsin deficiency . ERSD can be congenital or acquired. The congenital form is associated with the accumulation of only one protein, due to its altered structure. The accumulation is permanent and affects mainly the rough endoplasmic reticulum (RER). The most common cause of this condition is α1-antitrypsin deficiency. Acquired [secondary] form occurs due to exogenous agents or in the presence of concomitant diseases such as infections, and therefore structurally normal proteins accumulate in several cellular organelles.
In this article, we report a case of fibrinogen storage disease of the liver secondary to the use of oral contraceptives. This is the first reported case of fibrinogen storage disease secondary to estrogen ingestion. Informed consent was obtained from the patient regarding her recruitment in this case study.
A forty-year-old female was referred to our department for evaluation of elevated liver enzymes in May, 2004. She had no systemic symptoms. A year before, she had had a total abdominal hysterectomy and bilateral salpingo-oophorectomy. Since then, she had been on hormone replacement therapy with estrogen. Six months ago, during her routine follow-up, elevation of transaminase levels was noted. This elevation persisted for the next 6 months. She was then referred to our department for further investigation.
Laboratory features of the patient with exogenous estrogen
Aspartate aminotransferase (IU/L)
Alanine aminotransferase (IU/L)
Lactate dehydrogenase (IU/L)
Alkaline phosphatase (IU/L)
Total bilirubin (mg/dl)
Blood urea nitrogen (mg/dl)
Total cholesterol (mg/dl)
Blood glucose (mg/dl)
Blood ammonium-N (mg/dl)
The patient had elevated transaminase levels without any accompanying clinical symptoms. Her first liver biopsy revealed cytoplasmic inclusion bodies within hepatocytes associated with chronic hepatitis and mild fibrotic activity. The inclusions were sharply bordered and faintly eosinophilic together with a ground-glass appearance. They were negative to PAS and colloidal iron; therefore type IV glycogenoses and Lafora's disease were ruled out on morphological grounds, respectively. No staining with hepatitis antigens and α1-antitrypsin was observed immunohistochemically. Diffuse and strong positivity for fibrinogen was observed. Her serum fibrinogen levels, in addition to prothrombin, partial thromboplastin and thrombin times – excluding dysfibrinogenemia – were within normal limits. The patient was not the offspring of a consanguineous marriage.
Fibrinogen storage in hepatocytes has been previously reported in patients with or without hypofibrinogenemia. The disease was first shown in German families as a familial hypofibrinogenemia [4, 5]. Later, specific mutations in hereditary cases were reported [6, 7]. Callea et al., placed fibrinogen storage disorders in the ERSD group along with α1-antitrypsin and α1-antichymotrypsin deficiencies, and proposed a classification of fibrinogen storage diseases based on morphologic and clinical evidence, and thus divided the entity into three types . In type I, the inclusions are defined as round or polygonal, weakly eosinophilic cytoplasmic deposits with irregular borders. This type is a hereditary hypofibrinogenemia, genetically characterized by the presence of mutant variants of the fibrinogen molecule, namely fibrinogen Brescia and fibrinogen Aguadilla [3, 6, 7]. The other two types are rarer. Type II inclusions are large, hyaline bodies that occupy the entire cytoplasm and result in a ground-glass appearance, while round, eosinophilic globules surrounded by a clear halo constitute the inclusions of type III. At the ultrastructural level, type I inclusions are characterized by the presence of densely packed tubular structures, arranged in curved bundles resulting in a finger-print-like appearance. Type II inclusions appear as granular or fragmented fibrillar material and type III inclusions contain a central core resembling the tubular structures of Type I and a surrounding similar to that of Type II. In all types, the inclusions correspond to dilated cisternae of RER.
Cases of fibrinogen storage disease without hypofibrinogenemia have been recently reported. One such patient had atypical type of cytoplasmic inclusions and was considered to demonstrate a congenital case . Two other patients revealed fibrinogen storage in the liver during an acute infectious episode together with Type II inclusions. The latter were thought to have transient, acquired forms of the disease .
The inclusions observed in our patient were large, hyaline bodies occupying the entire cytoplasm, resulting in a ground-glass appearance. This morphology is consistent with Type II inclusions. Neither the characteristics of Type I inclusions, such as irregular borders, a clear halo surrounding the inclusion or an acicular shape, nor the findings consistent with Type III inclusions [round, eosinophilic globules with a clear halo around] were present in our patient. Electron microscopy revealed homogenous, granular material within dilated ER, which are also the characteristics of Type II inclusions. Tubular structures found in Type I and partially in Type III inclusions were not present either. These findings allowed us to consider the patient's inclusions to be Type II.
In the first biopsy, fibrinogen storage was accompanied with accumulation of complement 4 and α fetoprotein. This simultaneous deposition of multiple proteins destined for secretion indicates a dysfunction in the secretory apparatus, rather than the retention of a single mutant protein . Callea et al., claimed that this finding may help distinguish between the acquired and congenital forms of the disease . A single, genetically abnormal protein cannot be translocated from RER to smooth endoplasmic reticulum (SER), therefore it accumulates in RER . This type of selective and exclusive retention of fibrinogen defines the congenital and the more frequent form of the disease. On the other hand, structurally normal proteins can get trapped in RER, SER and/or secretory vesicles due to a secretory dysfunction, which might be caused by exogenous agents like alcohol, and by drugs such as colchicine . Thus in our case, a drug-induced, acquired form of fibrinogen storage is further supported by the above findings as well as the dramatic resolution of histopathologic and biochemical parameters after cessation of estrogen administration.
We ascribed the findings of chronic hepatitis and mild fibrotic activity in our patient to fibrinogen storage. Indeed, cases without hypofibrinogenemia, as well as those with hereditary hypofibrinogenemia and those that have a mutational basis, were shown to develop chronic hepatitis, fibrosis or cirrhosis, in the literature [3, 4, 8, 9]. Importantly, low levels of fibrinogen does not necessarily accompany the hepatic storage of fibrinogen, which was the case in our patient. This may also support the secondary, acquired nature of the disease.
Relying on the results explained above, we conclude that, in our patient an oral regimen of estrogen is associated with fibrinogen storage disorder. To our knowledge, this is the first case reported to date to show hepatic fibrinogen storage secondary to estrogen ingestion. The liver biopsies of patients with idiopathic liver enzyme abnormalities should be carefully evaluated for cytoplasmic inclusion bodies and, although rare, fibrinogen deposits.
- Hashimoto K, Hoshii Y, Takahashi M, Mitsuno S, Hanai N, Watanabe Y, Ishihara T: Use of monoclonal antibody against Lafora bodies for the immunocytochemical study of ground-glass inclusions in hepatocytes due to cyanamide. Histopathology. 2001, 39: 60-65. 10.1046/j.1365-2559.2001.01127.x.View ArticlePubMedGoogle Scholar
- Vazquez JJ: Ground-glass hepatocytes: light and electron microscopy. Characterization of the different types. Histol Histopathol. 1990, 5: 379-386.PubMedGoogle Scholar
- Callea F, Brisigotti M, Fabbretti G, Bonino F, Desmet VJ: Hepatic endoplasmic reticulum storage diseases. Liver. 1992, 12: 357-362.View ArticlePubMedGoogle Scholar
- Wehinger H, Klineg O, Alexandrakis E, Schumann J, Witt J, Seydewitz HH: Hereditary hypofibrinogenaemia with fibrinogen storage in the liver. Eur J Pediatr. 1983, 141: 109-112. 10.1007/BF00496800.View ArticlePubMedGoogle Scholar
- Pfeifer U, Ormanns W, Klinge O: Hepatocellular fibrinogen storage in familial hypofibrinogenemia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1981, 36: 247-55.View ArticlePubMedGoogle Scholar
- Brennan SO, Wyatt J, Medicina D, Callea F, George PM: Fibrinogen Brescia: hepatic endoplasmic reticulum storage and hypofibrogenaemia because of a gamma 284 Gly Arg mutation. Am J Pathol. 2000, 157: 189-196.View ArticlePubMedPubMed CentralGoogle Scholar
- Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM: Novel fibrinogen gamma375 Arg-->Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology. 2002, 36: 652-8. 10.1053/jhep.2002.35063.View ArticlePubMedGoogle Scholar
- Abukawa D, Tazawa Y, Noro T, Nakagawa M, Iinuma K, Sugiyama K, Knisely AS: Cytoplasmic inclusion bodies and minimal hepatitis: fibrinogen storage without hypo-fibrogenaemia. Pediatr Dev Pathol. 2001, 4: 304-309. 10.1007/s100240010174.View ArticlePubMedGoogle Scholar
- Marucci G, Morandi L, Macchia S, Betts CM, Tardio ML, Monte Dal PR, Pession A, Foschini MP: Fibrinogen storage disease without hypofibrinogenemia associated with acute infection. Histopathology. 2003, 42: 22-5. 10.1046/j.1365-2559.2003.01551.x.View ArticlePubMedGoogle Scholar
- Ng IOL, Ng M, Lai ECS, Wu PC: Endoplasmic storage disease of liver: characterization of intracytoplasmic hyaline inclusions. Histopathology. 1989, 15: 473-81.View ArticlePubMedGoogle Scholar
- Medicina D, Fabbretti G, Brennan SO, George PM, Kudryk B, Callea F: Genetic and immunological characterization of fibrinogen inclusion bodies in patients with hepatic fibrinogen storage and liver disease. Ann N Y Acad Sci. 2001, 936: 522-5.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/5/36/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.